Amarin Corp Plcuk (AMRN) Selling, General & Administrative (2010 - 2026)
Amarin Corp Plcuk (AMRN) Selling, General & Administrative (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
SG&A (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
2.93 Bn |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
6.03 Bn |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
3.58 Bn |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
-4.92 Bn |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
2.70 Bn |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
1.60 Bn |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
1.45 Bn |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
2.96 Bn |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Amarin Corp Plcuk |
5.17 Bn |
5.00 Bn |
17.77 Mn |
21.12 Mn |
| Date | Value |
|---|
| Mar 31, 2026 |
21.12 Mn |
| Dec 31, 2025 |
82.82 Mn |
| Sep 30, 2025 |
9.01 Mn |
| Jun 30, 2025 |
38.67 Mn |
| Mar 31, 2025 |
8.65 Mn |
| Dec 31, 2024 |
123.81 Mn |
| Sep 30, 2024 |
36.90 Mn |
| Jun 30, 2024 |
9.39 Mn |
| Mar 31, 2024 |
39.89 Mn |
| Dec 31, 2023 |
43.94 Mn |
| Sep 30, 2023 |
45.46 Mn |
| Jun 30, 2023 |
50.95 Mn |
| Mar 31, 2023 |
59.59 Mn |
| Dec 31, 2022 |
68.13 Mn |
| Sep 30, 2022 |
58.75 Mn |
| Jun 30, 2022 |
86.89 Mn |
| Mar 31, 2022 |
90.65 Mn |
| Dec 31, 2021 |
92.37 Mn |
| Sep 30, 2021 |
102.97 Mn |
| Jun 30, 2021 |
107.20 Mn |
